{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:20:39Z","timestamp":1790223639529,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.msard.2022.103740","type":"journal-article","created":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T11:32:02Z","timestamp":1647084722000},"page":"103740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-3055","authenticated-orcid":false,"given":"Gianmarco","family":"Abbadessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Maida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Miele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Lavorgna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolama Alessandra","family":"Marfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cavalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.msard.2022.103740_bib0001","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.3390\/ijerph18158163","article-title":"CD19 cell count at baseline predicts B cell repopulation at 6 and 12 months in multiple sclerosis patients treated with Ocrelizumab","volume":"2","author":"Abbadessa","year":"2021","journal-title":"Int. J. Environ. Res. Public Health."},{"key":"10.1016\/j.msard.2022.103740_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102802","article-title":"Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis","volume":"49","author":"Capasso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103740_bib0003","unstructured":"Cellerino, M., et\u00a0al., 2021. Predictors of ocrelizumab effectiveness in patients with Multiple Sclerosis. Neurotherapeutics. 1\u201310. Advance online publication. 10.1007\/s13311-021-01104-8."},{"key":"10.1016\/j.msard.2022.103740_bib0004","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute."},{"issue":"2","key":"10.1016\/j.msard.2022.103740_bib0005","doi-asserted-by":"crossref","first-page":"e940","DOI":"10.1212\/NXI.0000000000000940","article-title":"Effect of Ocrelizumab in blood leukocytes of patients with primary progressive MS","volume":"8","author":"Fern\u00e1ndez-Velasco","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.103740_bib0006","doi-asserted-by":"crossref","unstructured":"Fiocca Vernengo, F., et\u00a0al., 2020. CD8+ T cell immunity is compromised by anti-CD20 treatment and rescued by interleukin-17A. mBio, 11(3), e00447\u201320. 10.1128\/mBio.00447-20.","DOI":"10.1128\/mBio.00447-20"},{"issue":"12","key":"10.1016\/j.msard.2022.103740_bib0007","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2021-220435","article-title":"B cell depletion impairs vaccination-induced CD8+ T cell responses in a type I interferon-dependent manner","volume":"80","author":"Graalmann","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.msard.2022.103740_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103740_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab\u2013A new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.msard.2022.103740_bib0012","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s00415-019-09690-6","article-title":"Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis","volume":"268","author":"Schweitzer","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.103740_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102186","article-title":"BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab","volume":"43","author":"Signoriello","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2022.103740_bib0014","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1007\/s00415-020-09930-0","article-title":"Diagnosis and management of multiple sclerosis\u2013MRI in clinical practice","volume":"267","author":"Tomassini","year":"2020","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2022.103740_bib0015","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822002553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822002553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:58:46Z","timestamp":1761901126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822002553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":13,"alternative-id":["S2211034822002553"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103740","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103740"}}